An assessment of 265 biopharmaceutical facilities in the 35 countries comprising the Europe, the Middle East and Africa (EMEA) region found that the combined production of the sites in 2014 was more than 2.4 million L. Among the sites, 26%, 18%, 15% manufactured recombinant proteins only, vaccines only, or “other” (excluding mAbs and blood processing), respectively. Of the facilities, 62%, 31%, 4% and 3% focused on their own products, contract manufacturing (CMO), both CMO and their own products, and contract research, respectively. More than 90% of the facilities were in Europe, with only 17 and 9 plants in the Middle East and Africa, respectively. Germany had the highest number of active sites, producing more than 300,000 L, while the UK and Irish sites together had the highest output at almost 350,000 L. At 90,000 L each, Ireland and Denmark had the largest sites. By the end of 2014, 106, 117 and 81 drugs were in phase I, II and III clinical trials, respectively. In these clinical trials, the most common types of therapies were mAbs, vaccines and recombinant proteins, at 41%, 25% and 10%, respectively.

Source: EVOLUTION Global Talent Attraction